Proton‐Driven Deformability Enables Nanozyme‐Integrated Vaccine for Enhanced Tumor Immunotherapy
Advanced Materials · 2026
DOI: 10.1002/adma.202509994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Jingyi An und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, Protons, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Program of Nanozyme Laboratory in Zhongyuan, the China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Cancer immunotherapy leveraging vaccine‐based approaches has emerged as a promising strategy for long‐term tumor regression and metastasis prevention. However, the design of effective vaccines remains challenging due to the need for efficient lymph node (LN) targeting, dendritic cell (DC) uptake, and robust cellular immunity activation. Here, a proton‐driven, multifunctional nanovaccine (PP@Pt‐OVA) is presented that combines intelligent morphology regulation and nanozyme catalysis to address these challenges. The nanovaccine, comprising PVP@Pt nanozymes and OVA 257–264 peptides encapsulated in PEG‐b‐PAE micelles, undergoes proton‐driven morphology transformation in acidic LN microenvironments, enhancing particle size and reducing PEGylation for optimized LN retention and DC uptake. Once internalized, PVP@Pt nanozyme catalyzes reactive oxygen species (ROS) production, facilitating endosomal escape, antigen cross‐presentation, and DC maturation. PP@Pt‐OVA demonstrated efficient LN targeting, robust CD8 + T cell activation, and significant tumor inhibition in both prophylactic and therapeutic melanoma models, with excellent biocompatibility and minimal systemic toxicity. These findings highlight the potential of PP@Pt‐OVA as a versatile nanovaccine platform, offering a rational design framework for overcoming the limitations of subunit vaccines and advancing cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanozyme Laboratory in Zhongyuan, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
- Nanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou University, Zhengzhou, Henan, 451163, China.
- CAS Engineering Laboratory for Nanozyme, Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
ORCID-Profile: Bing Jiang
Förderung
- National Natural Science Foundation of China
- Key Program of Nanozyme Laboratory in Zhongyuan
- the China Postdoctoral Science Foundation
- China Postdoctoral Science Special Foundation
- Grant for International Joint Research Project of the Institute of Medical Science, the University of Tokyo
Zitieren
APA
An, J., Yang, Y., Feng, Y., Wang, S., Wang, S., Zhang, B., Yan, X., & Jiang, B. (2026). Proton‐Driven Deformability Enables Nanozyme‐Integrated Vaccine for Enhanced Tumor Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202509994
Vancouver
An J, Yang Y, Feng Y, Wang S, Wang S, Zhang B, et al. Proton‐Driven Deformability Enables Nanozyme‐Integrated Vaccine for Enhanced Tumor Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202509994
BibTeX
@article{An2026,
author = {An, Jingyi and Yang, Yijie and Feng, Yiming and Wang, Shuyu and Wang, Shenghui and Zhang, Baohua and Yan, Xiyun and Jiang, Bing},
title = {Proton‐Driven Deformability Enables Nanozyme‐Integrated Vaccine for Enhanced Tumor Immunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202509994}
}
EUVIMED